Business
GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-- Previously updated positive safety data for the GTB-3550 Phase 1 trial in relapsed/refractory AML and MDS with first-in-human trials, providing
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"-- Previously updated positive safety data for the GTB-3550 Phase 1 trial in relapsed/refractory AML and MDS with first-in-human trials, providing proof-of-concept support\n -- GTB-3650, second-generation Tri-Specific Killer Engager (TriKE®) utilizing nanobody technology advanced into IND-enabling studies\n -- Two new patents were issued securing IP related to the TriKE® platform technology underpinning novel portfolio of molecules through 2036\n -- $35.8 million in cash and cash equivalents as of September 30 provides ample runway into 2023\n\n\nBEVERLY HILLS, Calif., Nov. 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the \"Company\") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced third quarter 2021 results for the period ended September 30, 2021.\n\n \n \n \n \n \n \n\n \n\"We have made significant progress in the advancement of the Company's proprietary portfolio of novel cancer killing TriKEs, and our recent strategic executive team transition has us well positioned for the future,\" noted Gregory Berk, MD, Interim CEO. \"The marked progress in the quarter included securing newly issued IP, which serves to further protect the commercial development of the TriKE platform through 2036. In September, we announced further proof of concept safety data in our first in human Phase 1 clinical trial and announced the start of IND-enabling studies with GTB-3650, which is the Company's second-generation TriKE based on camelid nanobody technology that has several advantages over traditional IgG monoclonal antibodies. We are focused on rapidly advancing our extensive TriKE platform of molecules targeting a variety of tumor types.\"\nAs the Company works toward the launch of initial IND-enabling studies for GTB-3650, our data published to date, highlights the therapeutic and commercial advantages of GTB-3650 compared to GTB-3550 including improved potency, enhanced binding affinity, a similar well-tolerated preclinical safety profile, and commercial manufacturing capabilities through our arrangement with Cytovance. The Company aims to accelerate the GTB-3650 IND enabling studies and subsequent Phase 1/2 study, for patients with relapsed/refractory acute myelogenous leukemia (AML) and h...